MOLECULAR PHARMACOLOGY

EDITOR: Raymond J. Dingledine, Emory University

ASSOCIATE EDITORS: P. Jeffrey Conn, Emory University
Michael M. Gottesman, National Institutes of Health
Brian K. Kobilka, Stanford University
Kenneth P. Minneman, Emory University
Edward T. Morgan, Emory University

MANAGING EDITOR: Wendy M. Wiley

EDITORIAL ASSISTANT: Esmeralda Galán

EDITORIAL AND ADVISORY BOARD

Nigel J. M. Birdsall, National Institute for Medical Research, Mill Hill, United Kingdom
Randi D. Blakeley, Vanderbilt University
Joël Bockaert, Centre National de la Recherche Scientifique, France
Edward Bresnick, University of Massachusetts Medical Center
Joan Heller Brown, University of California, San Diego
Marc G. Caron, Duke University
Charles Chavkin, University of Washington
John W. Daly, National Institutes of Health
Steven K. Fisher, University of Michigan
Alfred G. Gilman, University of Texas Southwestern Medical Center, Dallas
Robert I. Glazer, Georgetown University
Frank J. Gonzalez, National Cancer Institute
F. Peter Guengerich, Vanderbilt University
James R. Halfpert, University of Arizona
Heidi Hamm, University of Illinois College of Medicine
R. Adron Harris, University of Colorado Health Sciences Center, Denver
Stephen B. Howell, University of California, San Diego
Paul A. Insel, University of California, San Diego
Karl H. Jakobs, University of Essen, Germany
Eric F. Johnson, The Scripps Research Institute
Dennis R. Koop, Oregon Health Sciences University
Robert J. Lefkowitz, Duke University
Lee E. Limbird, Vanderbilt University
Thomas M. Lincoln, University of Alabama at Birmingham
Joel Linden, University of Virginia
Robert L. Macdonald, University of Michigan Medical Center
Ronald F. Mason, National Institute of Environmental Health Sciences
Mark L. Mayer, National Institutes of Health
James O. McNamara, Duke University
Richard J. Miller, University of Chicago
Graeme Milligan, University of Glasgow, Scotland
T. J. Murphy, Emory University
Charles E. Myers, Jr., University of Virginia Health Sciences Center
S. R. Nahorski, University of Leicester, United Kingdom
David L. Nelson, Lilly Research Laboratories
Eric J. Nestler, Yale University
Richard R. Neubig, University of Michigan
Kim A. Neve, Veterans Affairs Medical Center, Portland
Allan B. Okey, University of Toronto, Canada
Paul Ortiz de Montellano, University of California, San Francisco
Gerry S. Oxford, University of North Carolina at Chapel Hill
Eric M. Parker, Bristol-Myers Squibb Company
Alan Poland, University of Wisconsin
Michael A. Rogawski, National Institutes of Health
Darryle D. Scheppe, Eli Lilly and Company
Gary L. Stiles, Duke University
Catherine D. Strader, Merck Research Laboratories
Palmer Taylor, University of California, San Diego
Todd A. Verdoorn, Vanderbilt University
Michael J. Waring, University of Cambridge, England
David J. Waxman, Boston University
Gary L. Westbrook, Vollum Institute
Michael M. White, Medical College of Pennsylvania
Steven A. Wrighton, Lilly Research Laboratories

BOARD OF PUBLICATIONS TRUSTEES

Kenneth E. Moore, Chairman
Kay A. Croker, Executive Officer

Wendy M. Wiley

About the cover: Depiction of cross-sectioned stereo views of the 5-HT2A receptor complexes with ergonovine (cyan) and ergotamine (red). The helical backbones for transmembrane domains 3, 4, 6, and 7 are shown in yellow. A mutagenesis strategy was used to demonstrate the importance of receptor residues F340 and D155 (shown in gray) for docking with the ergoline nucleus. From Choudhary, M. S., N. Sacha, A. Uluer, R. A. Glennon, R. B. Westkaemper, and B. L. Roth. Different ergoline and ergopeptide binding to 5-hydroxytryptamine2A receptors: Ergolines require an aromatic residue at position 340 for high affinity binding. Mol. Pharmacol. 47:450–457 (1995).